01—Abstract
Summary
Summary of the 8-K filed April 23, 2025. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific (TMO) reported first quarter 2025 results for the period ended March 29, 2025, with revenue of $10.36 billiona, essentially flat versus $10.34 billion a year earlier.
Organic revenue growth was just 1%, with currency translation a 1-point headwind and no contribution from acquisitions or divestitures. Profitability was mixed: GAAP diluted EPS rose 15% to $3.98b, helped by lower amortization of acquisition intangibles and a lower tax provision, while adjusted EPS grew only 1% to $5.15. Adjusted operating margin contracted slightly to 21.9% from 22.0%, and GAAP operating margin improved to 16.6% from 16.1%.
Restructuring costs rose to $98 millionc from $29 million. Cash generation weakened meaningfully. Operating cash flow fell to $723 million from $1.25 billion, and free cash flow dropped to $373 million from $908 million, driven by a $1.4 billion outflow from changes in working capital.
Management nonetheless continued capital deployment: it repurchased $2.0 billiond of stock, raised the dividend 10%, and agreed to acquire Solventum's Purification & Filtration business for $4.1 billion in cash. Total debt rose, with long-term obligations increasing to $31.4 billion from $29.1 billion, though cash and short-term investments also increased. The company did not provide updated 2025 guidance in this filing; it was deferred to the earnings call.
For investors, the quarter shows steady but low-growth top-line performance in a more uncertain macroeconomic environment, with earnings growth driven more by share count reduction and tax and amortization effects than by operations. The key items to monitor are the revised 2025 guidance, the working capital reversal that depressed free cash flow, and the integration and leverage implications of the Solventum acquisition.
02—Key points
Key Highlights
- Revenue of $10.36 billion was nearly flat year over year (+0.2%), with organic growth of only 1% and a 1-point currency headwind.
- GAAP diluted EPS rose 15% to $3.98, while adjusted EPS grew just 1% to $5.15, indicating earnings growth was largely driven by non-operating and accounting factors.
- Adjusted operating margin declined slightly to 21.9% from 22.0%, while GAAP operating margin improved to 16.6% from 16.1%, aided by lower acquisition-related amortization.
- Free cash flow fell 59% to $373 million from $908 million, as operating cash flow dropped to $723 million amid a $1.4 billion working capital outflow.
- Capital returns remained strong: $2.0 billion in share repurchases and a 10% dividend increase.
- Agreed to acquire Solventum's Purification & Filtration business for $4.1 billion in cash, a significant pending acquisition.
- Long-term obligations increased to $31.4 billion from $29.1 billion, and 2025 guidance update was deferred to the earnings call.
03—Questions
Frequently Asked Questions
Did Thermo Fisher grow its revenue and earnings in Q1 2025?
Revenue was essentially flat at $10.36 billion versus $10.34 billion, with 1% organic growth. GAAP diluted EPS rose 15% to $3.98, but adjusted EPS grew only 1% to $5.15, so most of the GAAP improvement reflects lower amortization and tax effects rather than stronger operations.
Why did free cash flow decline so sharply?
Free cash flow fell to $373 million from $908 million. Operating cash flow dropped to $723 million from $1.25 billion, mainly due to a $1.4 billion outflow from changes in assets and liabilities (working capital), partially offset by higher net income. Capital expenditures were broadly stable at $362 million.
What is the significance of the Solventum Purification & Filtration acquisition?
Thermo Fisher agreed to acquire Solventum's Purification & Filtration business for $4.1 billion in cash. Investors should watch how it is financed, given rising debt, and whether it adds meaningful organic growth and margin accretion once closed. The filing does not provide detailed financial contributions or closing timing.
Did the company update its 2025 financial outlook?
The filing does not include updated 2025 guidance. Management stated it would provide revised guidance during the earnings conference call on April 23, 2025, at 8:30 a.m. Eastern Time, so investors should review the call materials for those figures.
How is the company returning capital to shareholders?
In the quarter, Thermo Fisher repurchased $2.0 billion of common stock and paid $149 million in dividends, and it raised its dividend by 10%. Share repurchases helped reduce diluted weighted average shares to 379 million from 384 million, supporting per-share earnings growth.
04—Continue